Impact of Statin Therapy on Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation (from the CREDO-Kyoto Registry Cohort-2)

详细信息    查看全文

• 作者：Masahiro Natsuaki ; MD^a ; Yoshihisa Nakagawa ; MD^c ; ^{nakagawa@tenriyorozu.jp} ; Takeshi Morimoto ; MD^b ; Koh Ono ; MD^a ; Satoshi Shizuta ; MD^a ; Yutaka Furukawa ; MD^d ; Kazushige Kadota ; MD^e ; Masashi Iwabuchi ; MD^f ; Yoshihiro Kato ; MD^g ; Satoru Suwa ; MD^h ; Tsukasa Inada ; MDⁱ ; Osamu Doi ; MD^j ; Akinori Takizawa ; MD^k ; Masakiyo Nobuyoshi ; MD^f ; Toru Kita ; MD^d ; Takeshi Kimura ; MD^a ; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
• 刊名：The American Journal of Cardiology
• 出版年：2012
• 出版时间：15 May, 2012
• 年：2012
• 卷：109
• 期：10
• 页码：1387-1396
• 全文大小：514 K

文摘

Therapeutic strategies preventing late target lesion revascularization (TLR) after drug-eluting stent implantation have not been yet adequately investigated. In 13,087 consecutive patients undergoing first percutaneous coronary intervention in the CREDO-Kyoto Registry Cohort-2, we identified 10,221 patients who were discharged alive after implantation of sirolimus-eluting stents (SESs) only (SES stratum 5,029) or bare-metal stents (BMSs) only (BMS stratum 5,192). Impact of statin therapy at time of discharge from the index hospitalization on early (within the first year) and late (1 year to 4 years) TLR, was assessed in the SES stratum (statin group 2,735; nonstatin group 2,294) and in the BMS stratum (statin group 2,576; nonstatin group 2,616). Despite a significantly lower incidence of early TLR (7.8 % vs 22.2 % , p <0.0001), SES use compared to BMS use was associated with a significantly higher incidence of late TLR (7.7 % vs 3.0 % , p <0.0001). In the SES and BMS strata, the incidence of early TLR was similar regardless of statin use. In the SES stratum, the incidence of late TLR was significantly lower in the statin group than in the nonstatin group (6.1 % vs 9.6 % , p = 0.002), whereas no significant difference was found in the BMS stratum (2.6 % vs 3.3 % , p = 0.38). After adjusting confounders, risk for late TLR significantly favored statin use in the SES stratum (hazard ratio 0.73, 95 % confidence interval 0.54 to 0.98, p = 0.04), whereas the risk decrease was not significant in the BMS stratum (hazard ratio 0.74, 95 % confidence interval 0.46 to 1.20, p = 0.23). In conclusion, statin therapy at hospital discharge was associated with a significantly lower risk for late TLR after SES implantation.